Literature DB >> 28510066

The Delta Opioid Receptor in Pain Control.

Khaled Abdallah1,2,3,4, Louis Gendron5,6,7,8,9,10.   

Abstract

Nowadays, the delta opioid receptor (DOPr) represents a promising target for the treatment of chronic pain and emotional disorders. Despite the fact that they produce limited antinociceptive effects in healthy animals and in most acute pain models, DOPr agonists have shown efficacy in various chronic pain models. In this chapter, we review the progresses that have been made over the last decades in understanding the role played by DOPr in the control of pain. More specifically, the distribution of DOPr within the central nervous system and along pain pathways is presented. We also summarize the literature supporting a role for DOPr in acute, tonic, and chronic pain models, as well as the mechanisms regulating its activity under specific conditions. Finally, novel compounds that have make their way to clinical trials are discussed.

Entities:  

Keywords:  Analgesia; Antinociception; Delta opioid receptor; Pain; Pain pathways

Mesh:

Substances:

Year:  2018        PMID: 28510066     DOI: 10.1007/164_2017_32

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  12 in total

1.  Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA.

Authors:  Ariful Islam; Mohammad Atiqur Rahman; Megan B Brenner; Allamar Moore; Alyssa Kellmyer; Harley M Buechler; Frank DiGiorgio; Vincent R Verchio; Laura McCracken; Mousumi Sumi; Robert Hartley; Joseph R Lizza; Gustavo Moura-Letts; Bradford D Fischer; Thomas M Keck
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-27

2.  In vivo mapping of a GPCR interactome using knockin mice.

Authors:  Jade Degrandmaison; Khaled Abdallah; Véronique Blais; Samuel Génier; Marie-Pier Lalumière; Francis Bergeron; Catherine M Cahill; Jim Boulter; Christine L Lavoie; Jean-Luc Parent; Louis Gendron
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-26       Impact factor: 11.205

3.  Dual immuno-renal targeting of 7-benzylidenenaltrexone alleviates lupus nephritis via FcγRIIB and HO-1.

Authors:  Tsung-Chih Tseng; Duen-Yi Huang; Liang-Chuan Lai; Haw Hwai; Yi-Wen Hsiao; Jyun-Pei Jhou; Eric Y Chuang; Shiang-Jong Tzeng
Journal:  J Mol Med (Berl)       Date:  2018-03-05       Impact factor: 4.599

Review 4.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

5.  Pharmacogenomics of Opioid Treatment for Pain Management.

Authors:  Sarahbeth Howes; Alexandra R Cloutet; Jaeyeon Kweon; Taylor L Powell; Daniel Raza; Elyse M Cornett; Alan D Kaye
Journal:  Methods Mol Biol       Date:  2022

6.  Modulating β-arrestin 2 recruitment at the δ- and μ-opioid receptors using peptidomimetic ligands.

Authors:  Krishna K Sharma; Robert J Cassell; Yazan J Meqbil; Hongyu Su; Arryn T Blaine; Benjamin R Cummins; Kendall L Mores; David K Johnson; Richard M van Rijn; Ryan A Altman
Journal:  RSC Med Chem       Date:  2021-08-16

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 8.  From Pleasure to Pain, and Back Again: The Intricate Relationship Between Alcohol and Nociception.

Authors:  Meridith T Robins; Mary M Heinricher; Andrey E Ryabinin
Journal:  Alcohol Alcohol       Date:  2019-12-01       Impact factor: 2.826

9.  Ligand-specific recycling profiles determine distinct potential for chronic analgesic tolerance of delta-opioid receptor (DOPr) agonists.

Authors:  Hanieh Bagheri Tudashki; Youssef Haddad; Iness Charfi; Rejean Couture; Graciela Pineyro
Journal:  J Cell Mol Med       Date:  2020-04-12       Impact factor: 5.310

10.  Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.

Authors:  Anika Mann; Sophia Liebetrau; Marie Klima; Pooja Dasgupta; Dominique Massotte; Stefan Schulz
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.